Dr. Zelenetz on Potential of Acalabrutinib and BGB-3111 in CLL

Video

In Partnership With:

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses the potential with acalabrutinib and BGB-3111 for the treatment of patients with chronic lymphocytic leukemia (CLL).

Andrew D. Zelenetz, MD, PhD, medical director of Quality Informatics at Memorial Sloan Kettering Cancer Center, discusses the potential with acalabrutinib and BGB-3111 for the treatment of patients with chronic lymphocytic leukemia (CLL).

Acalabrutinib and BGB-3111 are described by Zelenetz as "pseudo" next-generation drugs, as they both have similar mechanisms of action. Additionally, they both bind to the active site cysteine and covalently modify the drug.

Moreover, it is known that acalabrutinib and BGB-3111 do not interfere with antibody-dependent cell-mediated cytotoxicity in culture. Therefore, they should play better in vivo with monoclonal antibodies but this has to be proven. Zelenetz adds that there should be fewer T-cell effects with both agents, and that they can achieve high levels of occupancy of BTK and are very active in patients with CLL.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,